CHIMERABIO
ChimeraBio is a biological investment firm specialized in seed and early stage venture investments.
CHIMERABIO
Status:
Active
Similar Organizations
ExploreBio
ExploreBio is an investment firm specializing in the pre-seed and early-stage venture capital investments.
Haller Capital
Haller Capital is an Austrian investment fund specialized in seed- and early-stage venture, and grant investments.
L&P Investments
L&P Investments is a micro-venture capital firm specialized in seed and early stage venture investments.
Molins Capital Inversión
Molins Capital Inversión, SCR, S.A. specializes in early stage and mid venture investments.
PKS Capital
PKS Capital is a U.S.-based investment firm specialized in seed- and early-stage venture investments.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2014-06-17 | Ocutec | ChimeraBio investment in Seed Round - Ocutec | 500 K GBP |
| 2010-03-17 | Sistemic | ChimeraBio investment in Series A - Sistemic | 1000 K USD |
More informations about "ChimeraBio"
Chimera Bioengineering - Crunchbase Company Profile …
Chimera solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program of the immune system.See details»
Chimera Bioengineering - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Chimera Bioengineering. Use the PitchBook Platform to explore the full profile.See details»
Home - Chimeron Bio | Redefining Cancer Therapeutics
Apr 16, 2024 Harnessing Genetic Medicine & saRNA to Transform Oncology Developing in vivo CAR, immuno-oncology, and cancer vaccine therapeutics. OUR UNIQUE APPROACH Our …See details»
CAR-T Cell Therapy | Chimera Bioengineering | South San Francisco
Chimera Bioengineering has built CAR-T cells with a novel genetic engineering technology to address the challenges in the field of cell therapy. Learn more about our scientific pipeline …See details»
Chimera Bioengineering - VentureRadar
Chimera Bioengineering, a biotherapeutics company, is building CAR T therapeutics for solid cancers programmed with RNA based gene regulatory systems to produce potent therapeutic …See details»
Science - Chimera Bio
Chimera has created novel CAR-T cells with genetic engineering technology to address the challenges in the field of cell therapy. Learn more about our scientific pipeline targeting solid tumors.See details»
Chimera Bioengineering Company Profile | Management and
Find contact information for Chimera Bioengineering. Learn about their Research & Development, Business Services market share, competitors, and Chimera Bioengineering's email format.See details»
CHIMERA BIO - Optimizing Drug Combinations of …
Proof of Concept Combination therapy for Renal cancer. Synergistic drug combination containing CI-994, tabacin, erlotinib and desatinib. Patent filed September 24th 2019, UNIGE licenced by Chimera Bio B.V. in 2022. A total of …See details»
Chimera Bioengineering - Craft
Chimera Bioengineering has 5 employees at their 1 location. See insights on Chimera Bioengineering including office locations, competitors, revenue, financials, executives, …See details»
ChimeraBio - Investments, Portfolio & Company Exits - Crunchbase
ChimeraBio is a biological investment firm specialized in seed and early stage venture investments.See details»
Chimera Bio - Raised $17.3M Funding from 5 investors - Tracxn
Mar 9, 2025 Chimera Bio has raised a total funding of $17.3M over 3 rounds from 5 investors. Investors include The Angels’ Forum, Illumina and 3 others. Their latest funding round was of …See details»
Ben Wang | Chimera Bioengineering
Ben Wang, Ph.D. is the co-founder and Chief Operating Officer of Chimera. He holds a Ph.D. from MIT.See details»
Chimera Bioengineering - VentureRadar
"Chimera Bioengineering, a biotherapeutics company, is building CAR T therapeutics for solid cancers programmed with RNA based gene regulatory systems to produce potent therapeutic …See details»
ChimeraBio – Investors Database – Unicorn Nest
Discover reliable insights Leverage validated data, identify key contacts and secure funding opportunities for your business.See details»
Chimera Appoints New CEO, Wins AFCR BRACE Award, and …
Company appoints Vlad Hogenhuis, M.D., as Chief Executive Officer Chimera selected as the winner of the Asian Fund for Cancer Research’s (AFCR) 2021 BRACE Award Venture …See details»
ChimeraBio and Scottish Enterprise co-invest in Sistemic
ChimeraBio and Scottish Enterprise’s Scottish Co-Investment Fund have co-led an undisclosed first round of funding for Glasgow-based biotech company Sistemic.See details»
Chimera Bioengineering | VentureRadar
Chimera Bioengineering, a biotherapeutics company, is building CAR T therapeutics for solid cancers programmed with RNA based gene regulatory systems to produce potent therapeutic …See details»
Mimicry of molecular glues using dual covalent chimeras
1 day ago The authors report the development of dual covalent proximity inducing molecules capable of selectively cross-linking two non-interacting proteins. Through the selective …See details»
ChimeraBio - Crunchbase
ChimeraBio is a biological investment firm specialized in seed and early stage venture investments.See details»
Gus Zeiner - Chimera Bio
Gus Zeiner is the Co-Founder and Chief Scientific Officer of Chimera Bio. He holds a Ph.D. from UCLA.See details»